Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-world Prospective Cohort Study of Patients With Moderate to Severe Acne Vulgaris Treated With Sarecycline (Seysara®) In Community Practice Settings in the U.S

NCT04820673 is registered in ClinicalTrials.gov with Almirall, S.A. as lead sponsor.

NCT NCT04820673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04820673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-world Prospective Cohort Study of Patients With Moderate to Severe Acne Vulgaris Treated With Sarecycline (Seysara®) In Community Practice Settings in the U.S
Lead sponsor
Almirall, S.A.
Phase
Observational
Overall status
Completed
Start date
March 9, 2021
Completion date
May 4, 2022
Enrollment
300 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acne vulgaris